The Role of Incorporating Acacia Gum in Foods on Glucose Homeostasis in Healthy Humans (AcaciaGlu)

February 10, 2026 updated by: Mai Khatib, King Abdulaziz University

The Role of Incorporating Acacia Gum in Foods on Glucose Homeostasis in Healthy Humans: a Pilot Study

Abnormal postprandial blood glucose (PPG) is considered as a strong predictor for developing metabolic diseases worldwide. Nowadays, little understanding is available on how a carbohydrate-rich food matrix and the starch structures within interact with the gastrointestinal tract to help in controlling PPG. In this investigation, the use Acacia gum enriched flour will be used to explore the effect of adding the gum as food supplement on PPG in healthy humans.

Study Overview

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Jeddah, Saudi Arabia
        • King Fahd Medical Research center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Male and female self-reported healthy volunteers (aged 18 to 40 years)
  • Normal to overweight individuals (body mass index (BMI) 18.5-30 kg/m2) o BMI is equal to body weight (kg) divided by height squared (m2)

Exclusion Criteria:

  • History of substance abuse
  • Excessive alcohol intake
  • Pregnancy
  • Diabetes
  • Cardiovascular disease
  • Cancer
  • Any gastrointestinal disease e.g. irritable bowel syndrome or inflammatory bowel disease
  • Kidney disease
  • Liver disease
  • Pancreatitis
  • Use of medications likely to interfere with energy metabolism, appetite regulation and hormonal balance, including: anti-inflammatory drugs or steroids, antibiotics, androgens, phenytoin, erythromycin or thyroid hormones.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Acacia gum incorporated biscuits
incorporating acacia gum flour into commonly consume foods
No Intervention: control biscuits

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
postprandial blood glucose
Time Frame: 0 minutes and postprandial timepoints: 15 minutes, 30 minutes, 60 minutes,120 minutes,180 minutes
0 minutes and postprandial timepoints: 15 minutes, 30 minutes, 60 minutes,120 minutes,180 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2023

Primary Completion (Actual)

August 30, 2023

Study Completion (Actual)

September 30, 2023

Study Registration Dates

First Submitted

January 30, 2026

First Submitted That Met QC Criteria

February 10, 2026

First Posted (Actual)

February 18, 2026

Study Record Updates

Last Update Posted (Actual)

February 18, 2026

Last Update Submitted That Met QC Criteria

February 10, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 286-22
  • 596-290-1443 (Other Grant/Funding Number: The Deanship of Scientific Research (DSR) at King Abdulaziz University (KAU), Jeddah, Saudi Arabia)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Health Adult Subjects

Subscribe